Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding Aligos Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 33 | 41 | +8 |
| Shares | 2.65M | 2.81M | +159.5K (+6.0%) |
| Value | $26.0M | $26.2M | +$208.1K (+0.8%) |
New holders (13)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 268,664 | $2.50M | 0.00% |
| SummitTX Capital, L.P. | 139,424 | $1.30M | 0.04% |
| Verition Fund Management LLC | 71,254 | $664.1K | 0.00% |
| Jane Street Group, LLC | 24,293 | $226.4K | 0.00% |
| XTX Topco Ltd | 23,053 | $214.9K | 0.01% |
| Two Sigma Advisers, LP | 13,000 | $121.2K | 0.00% |
| DRW Securities, LLC | 11,950 | $111.4K | 0.01% |
| HRT Financial LP | 11,374 | $106.0K | 0.00% |
| FMR LLC | 4,972 | $46.3K | 0.00% |
| Clear Street Markets LLC | 500 | $4.66K | 0.00% |
| Wealth Enhancement Advisory Services, LLC | 0 | $3.50K | 0.00% |
| Triumph Capital Management | 135 | $1.26K | 0.00% |
| Citigroup Inc | 1 | $9 | 0.00% |
Sold out (5)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Readystate Asset Management LP | 203,113 | $1.99M |
| Adage Capital Partners GP, L.L.C. | 140,000 | $1.37M |
| Squarepoint Ops LLC | 30,493 | $298.8K |
| Susquehanna International Group, LLP | 10,107 | $99.0K |
| Barclays PLC | 15 | $147 |